Aygün Ertuğrul

Aygün Ertuğrul

Auto-generated profile, based on publicly available information

Aygün Ertuğrul

Hacettepe University

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2021 in Pharmacopsychiatry
Verified
Journal Article
Closed access
PDF file
JLJose de Leon
Jose de Leon
GSGeorgios Schoretsanitis
Georgios Schoretsanitis
RSRobert L. Smith
Robert L. Smith
EMEspen Molden
Espen Molden
ASAnssi Solismaa
Anssi Solismaa
DMDaniel Mueller
Daniel Mueller
This international guideline proposes improving clozapine package inserts worldwide by using ancestry-based dosing and titration. Adverse drug reaction (ADR) databases suggest that clozapine is the third most toxic drug in the United States (US), and it produces four times higher worldwide pneumonia mortality than that by agranulocytosis or myocarditis. For trough steady-state clozapine serum concentrations, the therapeutic reference range is narrow, from 350 to 600 ng/mL with the potential for toxicity and ADRs as concentrations increase. Clozapine is mainly metabolized by CYP1A2 (female non-smokers, the lowest dose; male smokers, the highest dose). Poor metabolizer status through phenotypic conversion is associated with co-prescription of inhibitors (including oral contraceptives and valproate), obesity, or inflammation with C-reactive protein (CRP) elevations. The Asian population (Pakistan to Japan) or the Americas’ original inhabitants have lower CYP1A2 activity and require lower clozapine doses to reach concentrations of 350 ng/mL. In the US, daily doses of 300–600 mg/day are recommended. Slow personalized titration may prevent early ADRs (including syncope, myocarditis, and pneumonia). This guideline defines six personalized titration schedules for inpatients: 1) ancestry from Asia or the original people from the Americas with lower metabolism (obesity or valproate) needing minimum therapeutic dosages of 75–150 mg/day, 2) ancestry from Asia or the original people from the Americas with average metabolism needing 175–300 mg/day, 3) European/Western Asian ancestry with lower metabolism (obesity or valproate) needing 100–200 mg/day, 4) European/Western Asian ancestry with average metabolism needing 250–400 mg/day, 5) in the US with ancestries other than from Asia or the original people from the Americas with lower clozapine metabolism (obesity or valproate) needing 150–300 mg/day, and 6) in the US with ancestries other than from Asia or the original people from the Americas with average clozapine metabolism needing 300–600 mg/day. Baseline and weekly CRP monitoring for at least four weeks is required to identify any inflammation, including inflammation secondary to clozapine rapid titration.

1 September 2014 in Psychiatry Research: Neuroimaging
Verified
Journal Article
Closed access
EOElcin Ozcelik-Eroglu
Elcin Ozcelik-Eroglu
AEAygun Ertugrul
Aygun Ertugrul
KOKader Karli Oguz
Kader Karli Oguz
AHArzu Ceylan Has
Arzu Ceylan Has
SKSevilay Karahan
Sevilay Karahan
MYMumin Kazim Yazici
Mumin Kazim Yazici

1 November 2009 in Psychiatry Research: Neuroimaging
Verified
Journal Article
Closed access
AEAygun Ertugrul
Aygun Ertugrul
BVBilge Volkan-Salanci
Bilge Volkan-Salanci
KBKoray Basar
Koray Basar
KOKader Karli Oguz
Kader Karli Oguz
BDBasaran Demir
Basaran Demir
BUBerna Ulug
Berna Ulug

24 March 2005 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Open access
PDF file
AEAygun Ertugrul
Aygun Ertugrul
AYA. Elif Anil Yagcioglu
A. Elif Anil Yagcioglu
NENurhayat Eni
Nurhayat Eni
KYKâzim M. Yazici
Kâzim M. Yazici
Abstract  The aim of the present study was to assess the occurence of obsessive‐compulsive symptoms (OCS) in schizophrenic patients treated with clozapine, and to examine the relationship between OCS and other clinical variables. The results support earlier findings which suggest that clozapine produces or unmasks OCS. In addition, the severity of OCS was not related to other dimensions of psychopathology, severity of illness, clinical improvement or dose and duration of clozapine treatment.

1 January 2007 in Psychiatry Research
Verified
Journal Article
Closed access
AEAygun Ertugrul
Aygun Ertugrul
GUGulberk Ucar
Gulberk Ucar
KBKoray Basar
Koray Basar
BDBasaran Demir
Basaran Demir
SYSamiye Yabanoglu
Samiye Yabanoglu
BUBerna Ulug
Berna Ulug

1 May 2005 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
AEAygun Ertugrul
Aygun Ertugrul
BDBasaran Demir
Basaran Demir